14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SHPH vs QNRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). SHPH carries a Unified Composite Score of 48.3/100 (HOLD) at $3.49 (N/M Forward P/E, 0.0% operating margin), whereas QNRX carries 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: SHPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 31.8); meanwhile QNRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SHPH vs QNRX. Trailing 12-month operating profitability (SHPH 0.0% vs QNRX 0.0%) and valuation multiples (SHPH N/M vs QNRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $16.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SHPH vs QNRX Key Questions & Quantitative Answers
As of Nov 20, 2026, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). SHPH carries a Unified Composite Score of 48.3/100 (HOLD) at $3.49 (N/M Forward P/E, 0.0% operating margin), whereas QNRX carries 46.1/100 (HOLD) at $3.28 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SHPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 31.8); meanwhile QNRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SHPH and QNRX split Growth & Scale metrics: SHPH posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with QNRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SHPH generates N/A in USD-normalized revenue versus N/A for QNRX. In operating R&D and SG&A reinvestment, SHPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QNRX.
QNRX screens cheaper on headline valuation multiples. SHPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas QNRX trades at N/M Forward P/E, 7.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SHPH (-90.0% ROE) versus QNRX (-142.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SHPH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (9.23β · 88% Vol realized risk). By comparison, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.